TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Average Rating of “Moderate Buy” by Analysts

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $9.00.

Several research analysts recently commented on the stock. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price for the company. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating on the stock. Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Citigroup assumed coverage on TuHURA Biosciences in a report on Monday, April 27th. They set an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences during the fourth quarter worth about $59,000. Jane Street Group LLC acquired a new stake in TuHURA Biosciences in the 1st quarter worth approximately $69,000. Geode Capital Management LLC boosted its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after purchasing an additional 307,260 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences during the 2nd quarter worth approximately $27,000. Finally, New York State Common Retirement Fund purchased a new stake in TuHURA Biosciences during the 2nd quarter worth approximately $97,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Price Performance

TuHURA Biosciences stock opened at $2.17 on Friday. The stock has a market cap of $138.50 million, a price-to-earnings ratio of -3.57 and a beta of -0.05. The firm has a 50-day moving average of $2.30 and a two-hundred day moving average of $1.89. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Research analysts expect that TuHURA Biosciences will post -0.56 earnings per share for the current year.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.